TrialBlood advances2020

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

Jennifer M Knight et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.